Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1864-1871

  Shaffer, Brian C ^a   Tallman, Martin ^a   Malone, Adriana K ^b   Reshef, Ran ^c   Litzow, Mark ^d   Liesveld, Jane ^e   Wiernik, Peter H ^f   Ahn, Kwang Woo ^g   Hu, Zhen Huan ^g   Saber, Wael ^g   Nishihori, Taiga ^h   Kharfan Dabaja, Mohamed A ^h   Valcárcel, David ⁱ   Grunwald, Michael R ^j   Fasan, Omotayo ^j   Copelan, Edward ^j   Wood, William Allen ^k   Rizzieri, David A ^l   Bacher, Ulrike ^m   Hamilton, Betty ⁿ   Gerds, Aaron ⁿ   Kalaycio, Matt ⁿ   Sobecks, Ron ⁿ   William, Basem ^o   Saad, Ayman ^p   Costa, Luciano J ^p   Cutler, Corey ^q   Alyea, Edwin ^q   Warlick, Erica ^r   Ustun, Celalettin ^r   Wirk, Baldeep Mona ^s   Sabloff, Mitchell ^t   Daly, Andrew ^u   Marks, David ^v   Gale, Robert Peter ^w   Olsson, Richard ^x   Miller, Alan M ^y   Kamble, Rammurti ^z   Cortes, Jorge ^aa   Popat, Uday ^aa   Kindwall Keller, Tamila L ^ab   Cahn, Jean Yves ^ac   Savani, Bipin N ^ad   Vij, Ravi ^ae   Maziarz, Richard ^af   Pavletic, Steven ^ag   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f OUR LADY OF MERCY MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Hospital Vall di'Hebron   (Spain)

^j Levine Cancer Institute   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^s SEATTLE CANCER CARE ALLIANCE   (United States)

^t OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^u TOM BAKER CANCER CENTRE   (Canada)

^v NATIONAL HEALTH SERVICE   (United Kingdom)

^w IMPERIAL COLLEGE LONDON   (United Kingdom)

^x KAROLINSKA INSTITUTE   (Sweden)

^y BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^z BAYLOR COLLEGE OF MEDICINE   (United States)

^aa UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ab UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^ac University of Grenoble CNRS FRE 3405   (France)

^ad VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ae WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^af OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ag NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CELL TRANSPLANTATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; KARNOFSKY PERFORMANCE STATUS; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; SCORING SYSTEM; ADOLESCENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84974539642     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.0515     Document Type: Article

References (29)

1. Cazzola M, Della Porta MG, Malcovati L: The genetic basis of myelodysplasia and its clinical relevance. Blood 122:4021-4034, 2013
2. Adès L, Itzykson R, Fenaux P: Myelodysplastic syndromes. Lancet 383:2239-2252, 2014
3. de Witte T, Hagemeijer A, Suciu S, et al: Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: Final results of a prospective randomized European Intergroup Trial. Haematologica 95:1754-1761, 2010
4. Valcárcel D, Martino R, Caballero D, et al: Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26:577-584, 2008
5. Lim Z, Brand R, Martino R, et al: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28: 405-411, 2010
6. Runde V, de Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Bone Marrow Transplant 21:255-261, 1998
7. Bartenstein M, Deeg HJ: Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 24:407-422, 2010
8. Bejar R, Stevenson KE, Caughey B, et al: Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 32:2691-2698, 2014
9. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
10. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
11. Della Porta MG, Alessandrino EP, Bacigalupo A, et al: Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 123: 2333-2342, 2014
12. Schanz J, Tüchler H, Solé F, et al: New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820-829, 2012
13. Greenberg P, Stone RM, Bejar R, et al: Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw 13:261-272, 2015
14. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579-585, 2004
15. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol 31:2662-2670, 2013
16. Horowitz M: The role of registries in facilitating clinical research in BMT: Examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 42:S1-S2, 2008 (suppl 1)
17. Breems DA, Van Putten WL, De Greef GE, et al: Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791-4797, 2008
18. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
19. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289-300, 1995
20. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
21. Gónen M, Heller G: Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92:965-970, 2005
22. Raykar VC, Steck H, Krishnapuram B, et al: On ranking in survival analysis: Bounds on the concordance index. Presented at the 21 Annual Conference on Neural Information Processing Systems, Vancouver, British Columbia, Canada, December 3-6, 2007
23. Koenecke C, Göhring G, de Wreede LC, et al: Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: A retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica 100: 400-408, 2015
24. Hwang KL, Song MK, Shin HJ, et al: Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine. Blood Res 49: 234-240, 2014
25. Ustun C, Trottier BJ, Sachs Z, et al: Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome. Biol Blood Marrow Transplant 21: 866-872, 2015
26. Deeg HJ, Scott BL, Fang M, et al: Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 120:1398-1408, 2012
27. Armand P, Gibson CJ, Cutler C, et al: A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120:905-913, 2012
28. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
29. Kröger N, Brand R, Niederwieser D, et al: Reduced intensity vs. standard conditioning followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the Chronic Malignancies Working Party of the EBMT (RICMAC-trial). Blood 124:320, 2014